TY - JOUR
T1 - Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity
AU - Martin, Mona L.
AU - Mccarrier, Kelly P.
AU - Chiou, Chiun Fang
AU - Gordon, Kenneth
AU - Kimball, Alexa B.
AU - Van Voorhees, Abby S.
AU - Gottlieb, Alice B.
AU - Huang, Xingyue
AU - Globe, Denise
AU - Chau, Dina
AU - Viswanathan, Hema N.
AU - Kricorian, Gregory
N1 - Funding Information:
Declaration of interest: This study was funded by Amgen Inc. MLM and KPM are employees of Health Research Associates, which received funding for this study from Amgen Inc. C-FC, XH, and DG are past employees and shareholders of Amgen Inc. KG has received honoraria from and served as a consultant to Abbott Laboratories, Amgen, Janssen Novartis, Pfizer, Merck and Lilly and has received grants from Abbott, Amgen, Janssen, Lilly and Celgene. ABK is an investigator and consultant for Merck, Pfizer, Abbott, Amgen, Janssen, Celgene, VBL and Idera. ASV is an investigator for Amgen. ABG has consulting/advisory board agreements with Amgen Inc., Astellas, Centocor (Janssen) Inc., Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs, TEVA, Actelion, UCB, Novo Nordisk, Novartis, DermiPsor Ltd., Incyte, Pfizer, Can-Fite, Lilly and Coronado; and has received research/educational grants (paid to Tufts Medical Center) from Centocor (Janssen), Amgen Inc., Immune Control, Abbott, Novo Nordisk, UCB, Novartis, Celgene, Pfizer and Lilly. DC, HNV and GK are employees and shareholders of Amgen Inc. Julia R. Gage, PhD, on behalf of Amgen Inc., provided assistance with writing the manuscript.
PY - 2013/8
Y1 - 2013/8
N2 - Objective: To develop and assess content validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome (PRO) measure of psoriasis symptoms. Methods: Following initial literature exploration and input from experts, concept elicitation was conducted in two rounds (focus groups and individual interviews) with 59 subjects with mild to severe psoriasis. Transcripts were coded to identify symptom concepts and develop a conceptual framework using ATLAS.ti software. Qualitative content analysis and clinical expert input supported item generation and development of a draft measure. Two rounds of face-to-face cognitive interviews with 40 subjects with moderate to severe psoriasis were conducted to test subject comprehension and content coverage. Results: Concepts of itching, scaling, flaking, tearing/cracking, burning, stinging, pain, bleeding and color of appearance were the most common symptom-related expressions. Saturation of concept was demonstrated. Severity was identified as the most meaningful attribute of psoriasis symptoms. A final 8-item measure was developed to assess patient-perceived symptom severity for itch, pain, burning, stinging, cracking, scaling, flaking and redness. Twenty-four-hour recall and 7-day recall versions were prepared for future quantitative assessment of measurement properties. Conclusions: The PSI is a short, low burden, patient-reported measure of psoriasis symptom severity with documented evidence of content validity.
AB - Objective: To develop and assess content validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome (PRO) measure of psoriasis symptoms. Methods: Following initial literature exploration and input from experts, concept elicitation was conducted in two rounds (focus groups and individual interviews) with 59 subjects with mild to severe psoriasis. Transcripts were coded to identify symptom concepts and develop a conceptual framework using ATLAS.ti software. Qualitative content analysis and clinical expert input supported item generation and development of a draft measure. Two rounds of face-to-face cognitive interviews with 40 subjects with moderate to severe psoriasis were conducted to test subject comprehension and content coverage. Results: Concepts of itching, scaling, flaking, tearing/cracking, burning, stinging, pain, bleeding and color of appearance were the most common symptom-related expressions. Saturation of concept was demonstrated. Severity was identified as the most meaningful attribute of psoriasis symptoms. A final 8-item measure was developed to assess patient-perceived symptom severity for itch, pain, burning, stinging, cracking, scaling, flaking and redness. Twenty-four-hour recall and 7-day recall versions were prepared for future quantitative assessment of measurement properties. Conclusions: The PSI is a short, low burden, patient-reported measure of psoriasis symptom severity with documented evidence of content validity.
KW - Content validity
KW - Patient-reported outcome
KW - Psoriasis
KW - Symptom
UR - http://www.scopus.com/inward/record.url?scp=84880214727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880214727&partnerID=8YFLogxK
U2 - 10.3109/09546634.2012.759639
DO - 10.3109/09546634.2012.759639
M3 - Article
C2 - 23249143
AN - SCOPUS:84880214727
SN - 0954-6634
VL - 24
SP - 255
EP - 260
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
IS - 4
ER -